Nektar Therapeutics (NKTR) is up 17.00% at $99.29 midday Monday, propelled by positive clinical trial results. In contrast, Energy Focus (EFOI) is down 11.71% to $5.73 after Friday’s circuit-breaker-triggering 242.11% surge drew a wave of profit-taking. Both stocks underscore a session marked by outsized intraday volatility.
52-Week Extension Results Catalyze Nektar’s Move
Nektar’s jump comes after the company reported new 52-week extension data from its REZOLVE-AA trial in severe-to-very-severe alopecia areata. The company highlighted that a growing proportion of patients achieved clinically meaningful hair regrowth, with improvements observed in key SALT (Severity of Alopecia Tool) measures—including SALT Score ≤20 and ≤30—as well as response markers SALT50 and SALT30. The source notes that placebo patients did not show similar gains, strengthening the efficacy case for rezpegaldesleukin.
On the safety front, Nektar said rezpegaldesleukin maintained a favorable tolerability profile through 52 weeks, with most treatment-related adverse events categorized as mild to moderate and resolving without intervention. The company stated these results support advancing rezpegaldesleukin into late-stage development for alopecia areata. NKTR is now trading near reported resistance levels, with the market weighing whether this data justifies a higher sustained value.
Energy Focus Retraces as Traders Lock In Friday’s Gains
Energy Focus, meanwhile, is experiencing a sharp pullback after its explosive performance last week. The stock fell 12.17% in premarket trading and is down 11.71% at the open, according to Benzinga data, following Friday's 242.11% rally. Friday’s move was triggered by updates on data center infrastructure work—specifically, the completion of Project G, a $0.5 million UPS system, and progress on Project Y, a $6.6 million contract running through 2027 with a leading Asian data center developer.
Momentum signals remain highly stretched: EFOI is 159.8% above its 20-day simple moving average and 170.2% above its 100-day SMA. The relative strength index (RSI) is at 94.71, an extremely overbought reading. The stock is also up 254.64% from its 52-week low of $1.43 over the past year.
No Stocks365 proprietary signals were registered for either name, with events appearing squarely catalyst-driven.
Stocks365 Take: Signals and Technical Triggers for This Week
The current momentum in NKTR is firmly linked to clinical data. The stock’s 17% intraday gain is typical of binary clinical catalysts. What sets this readout apart, based on Nektar’s data, is the strengthening response over time—a positive sign for longer-term efficacy, rather than a transient effect. Failure to consolidate above the $99.29 resistance area may suggest a risk of swift reversal before week’s end.
EFOI’s price action remains technically overextended, with both major averages and RSI at extremes. The market is watching whether Monday’s selling settles the stock into a new range or prompts a deeper reversion closer to the 52-week low, especially as traders digest whether the Project Y contract can anchor a sustainable earnings story.
Historical Market Parallels Informing Trader Psychology
NKTR’s surge evokes echoes of 2021 late-stage drug data rallies, where large biotech moves often saw partial retracements as investors focused on commercial and regulatory risks. However, rezpegaldesleukin’s unique mechanism and the matured alopecia areata market may provide a more defined regulatory path than those earlier cases.
Traders are watching whether EFOI’s $6.6 million project supports sustained gains or if Monday’s pullback signals the end of the re-rating.